The Utility of Circulating EGFR, EGF, and TGF-α as Biomarkers for Fluorescence Imaging in Head and Neck Cancer Tissues

Abstract Purpose EGFR (Epidermal growth factor receptor) is a prominent oncogene in HNSCC (Head and neck squamous cell carcinoma) and a major target for fluorescence-guided surgery (FGS). Soluble fragments of the EGFR axis including the extracellular domain fragment (sEGFR) and ligands EGF and TGF-α are detectable in serum, but their role as predictive biomarkers for fluorescence imaging remains unclear. This study determines whether circulating EGFR-axis biomarkers can stratify HNSCC patients suitable for EGFR-targeted FGS. Procedures Serum collected prior to antibody infusion from 47 HNSCC patients (including 27 patients who received panitumumab-IRDye800CW (PAN800) and 20 patients who did not receive PAN800) and 20 healthy controls was analyzed for various markers using ELISA. Tissue EGFR expression was assessed by IHC, and fluorescence metrics, mean fluorescence intensity (MFI) and tumor-to-background ratio (TBR) were quantified in resected specimens. Results sEGFR, sEGF, and TGF-α were significantly lower in HNSCC patients than healthy controls. Circulating biomarkers did not significantly influence tumor MFI. However, sEGFR showed a significant non-linear association with TBR (adjusted R 2 = 0.66, Spearman ρ = − 0.76; both p < 0.001). Tissue EGFR expression significantly predicted MFI (ρ = 0.52, p = 0.011) and TBR (ρ = 0.443, p = 0.034). ROC analysis identified sEGFR as an excellent preoperative predictor of adequate imaging contrast (TBR ≥ 2; AUC = 0.94, cutoff 23.3 ng/mL, sensitivity 100%, specificity 80%), with a composite sEGFR + sEGF model achieving AUC = 0.989 (sensitivity 94.4%, specificity 100%). Conclusions Soluble EGFR-axis components are biologically relevant, clinically accessible biomarkers that can stratify patient suitability for EGFR-targeted FGS. Trial registration ClinicalTrials.gov identifier: NCT04511078, Study start:12/08/2020, https://clinicaltrials.gov/study/NCT04511078?cond=NCT04511078%20&rank=1

Authors

Publication Details

Journal
Molecular Imaging and Biology
Published
2026-11-10
DOI
https://doi.org/10.1007/s11307-026-02149-x
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Utility of Circulating EGFR, EGF, and TGF-α as Biomarkers for Fluorescence Imaging in Head and Neck Cancer Tissues

Anthony B. Morlandt, Melad Dababneh, Benjamin B. Kasten, Syeda Maria Ahmad Zaidi et al.
Molecular Imaging and Biology
Head and Neck Cancer Studies
article

The Utility of Circulating EGFR, EGF, and TGF-α as Biomarkers for Fluorescence Imaging in Head and Neck Cancer Tissues

Anthony B. Morlandt, Melad Dababneh, Benjamin B. Kasten, Syeda Maria Ahmad Zaidi, Sherin James, Eben Lloyd Rosenthal, Anne C. Kane, Abbigael V. Eli, Brandee T. Brown, Nicolaus D. Knight, Akhilesh Wodeyar, Jackie Shi, Sherin James
article en

Abstract

Abstract Purpose EGFR (Epidermal growth factor receptor) is a prominent oncogene in HNSCC (Head and neck squamous cell carcinoma) and a major target for fluorescence-guided surgery (FGS). Soluble fragments of the EGFR axis including the extracellular domain fragment (sEGFR) and ligands EGF and TGF-α are detectable in serum, but their role as predictive biomarkers for fluorescence imaging remains unclear. This study determines whether circulating EGFR-axis biomarkers can stratify HNSCC patients suitable for EGFR-targeted FGS. Procedures Serum collected prior to antibody infusion from 47 HNSCC patients (including 27 patients who received panitumumab-IRDye800CW (PAN800) and 20 patients who did not receive PAN800) and 20 healthy controls was analyzed for various markers using ELISA. Tissue EGFR expression was assessed by IHC, and fluorescence metrics, mean fluorescence intensity (MFI) and tumor-to-background ratio (TBR) were quantified in resected specimens. Results sEGFR, sEGF, and TGF-α were significantly lower in HNSCC patients than healthy controls. Circulating biomarkers did not significantly influence tumor MFI. However, sEGFR showed a significant non-linear association with TBR (adjusted R 2 = 0.66, Spearman ρ = − 0.76; both p < 0.001). Tissue EGFR expression significantly predicted MFI (ρ = 0.52, p = 0.011) and TBR (ρ = 0.443, p = 0.034). ROC analysis identified sEGFR as an excellent preoperative predictor of adequate imaging contrast (TBR ≥ 2; AUC = 0.94, cutoff 23.3 ng/mL, sensitivity 100%, specificity 80%), with a composite sEGFR + sEGF model achieving AUC = 0.989 (sensitivity 94.4%, specificity 100%). Conclusions Soluble EGFR-axis components are biologically relevant, clinically accessible biomarkers that can stratify patient suitability for EGFR-targeted FGS. Trial registration ClinicalTrials.gov identifier: NCT04511078, Study start:12/08/2020, https://clinicaltrials.gov/study/NCT04511078?cond=NCT04511078%20&rank=1

Molecular Imaging and Biology
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon